Hospital
Prime Healthcare Services - ST. Mary's Passaic LLC
Prime Healthcare Services - ST. Mary's Passaic LLC was paid $56.16M by Medicaid between Jan 2018 and Dec 2024, across 295 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - ST. MARY'S PASSAIC LLC
PASSAIC, NJ 07055
PASSAIC, NJ 07055
33aNPI1770901761assigned 04/07/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$56.16M
24GClaims904,936
24DCodes billed295
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#30 of 93
Median peer was paid$30.60M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 139,456 | $8.53M | |
| 2019 | 120,853 | $8.03M | |
| 2020 | 85,290 | $6.59M | |
| 2021 | 122,411 | $7.58M | |
| 2022 | 158,734 | $9.10M | |
| 2023 | 157,796 | $8.84M | |
| 2024incomplete | 120,396 | $7.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 23,862 | 21,491 | $6.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 25,262 | 22,844 | $6.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 16,841 | 15,061 | $5.15M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 5.9% | 21,309 | 2,743 | $3.32M |
| OP272 | 5.1% | 20,440 | 16,877 | $2.88M | |
| OP710 | 3.2% | 10,508 | 8,669 | $1.77M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 2,929 | 2,677 | $1.59M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 3,060 | 2,800 | $1.47M |
| G0378 | Hospital observation service, per hour | 2.6% | 7,264 | 5,159 | $1.46M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.3% | 3,125 | 2,819 | $1.31M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.2% | 13,093 | 5,068 | $1.23M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 5,466 | 4,900 | $1.09M |
283 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 11,752 | $1.06M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.9% | 6,768 | $1.05M |
| 58558 | 1.8% | 782 | $985K | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.5% | 10,317 | $860K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 1,946 | $798K |
| OP370 | 1.2% | 11,297 | $653K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 9,851 | $644K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.0% | 1,486 | $565K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,045 | $520K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,439 | $518K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,271 | $474K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,076 | $450K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,815 | $432K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,932 | $427K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,047 | $392K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,790 | $375K |
| 76641 | <1% | 2,743 | $368K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,855 | $366K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,847 | $364K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,029 | $360K |
| OP270 | <1% | 26,900 | $332K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,032 | $322K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,531 | $312K |
| 93017 | <1% | 1,906 | $292K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,087 | $288K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,330 | $255K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,810 | $243K |
| 73630 | <1% | 3,047 | $243K | |
| 73030 | <1% | 2,258 | $214K | |
| 80053 | Comprehensive metabolic panel | <1% | 23,748 | $208K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 807 | $206K |
| OP250 | <1% | 49,042 | $204K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,244 | $202K |
| 73562 | <1% | 1,739 | $201K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,283 | $199K |
| J3490 | Unclassified drugs | <1% | 14,329 | $188K |
| 73130 | <1% | 2,036 | $176K | |
| 93458 | <1% | 115 | $168K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,448 | $167K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,574 | $163K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 400 | $156K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 668 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,621 | $149K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,073 | $137K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,839 | $133K |
| 73610 | <1% | 2,283 | $130K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,797 | $129K |
| 77080 | <1% | 2,141 | $127K | |
| OP271 | <1% | 11,499 | $118K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,492 | $115K |
| 81025 | <1% | 20,486 | $114K | |
| 72100 | <1% | 1,902 | $113K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,223 | $110K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 771 | $108K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,647 | $106K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 543 | $101K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,513 | $100K |
| 88342 | <1% | 2,933 | $89K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 744 | $89K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,717 | $87K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 3,715 | $86K |
| OP259 | <1% | 14,614 | $86K | |
| 73110 | <1% | 914 | $84K | |
| C1769 | Guide wire | <1% | 750 | $83K |
| 76801 | <1% | 618 | $81K | |
| 59025 | Fetal non-stress test | <1% | 881 | $80K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,357 | $78K |
| 73564 | <1% | 715 | $74K | |
| 80320 | <1% | 3,291 | $73K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,589 | $72K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 672 | $70K |
| 77065 | Tomosynthesis, mammo | <1% | 526 | $69K |
| 99152 | <1% | 1,266 | $62K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 675 | $62K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 739 | $57K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,338 | $57K |
| 90715 | <1% | 1,245 | $55K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,279 | $55K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,875 | $52K |
| 97035 | <1% | 3,300 | $52K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,913 | $49K |
| 84484 | <1% | 7,573 | $47K | |
| C1781 | Mesh (implantable) | <1% | 59 | $47K |
| 83690 | <1% | 7,891 | $46K | |
| OP279 | <1% | 4,186 | $45K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,488 | $44K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 414 | $43K |
| 76642 | <1% | 468 | $43K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,277 | $42K |
| 81001 | <1% | 14,922 | $37K | |
| 83880 | <1% | 2,105 | $37K | |
| 72110 | <1% | 513 | $36K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 551 | $36K |
| 87070 | <1% | 4,128 | $36K | |
| 73502 | <1% | 838 | $36K | |
| 94060 | <1% | 300 | $36K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 513 | $34K |
| 84702 | <1% | 2,342 | $34K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,191 | $33K |
| 76770 | <1% | 361 | $32K | |
| 88313 | <1% | 884 | $32K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,536 | $30K |
| 88304 | <1% | 1,106 | $29K | |
| 87186 | <1% | 2,450 | $29K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,518 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,655 | $28K |
| 86850 | <1% | 2,587 | $28K | |
| 97161 | <1% | 460 | $27K | |
| 93970 | <1% | 218 | $27K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,590 | $27K |
| 76536 | <1% | 246 | $26K | |
| 85610 | <1% | 8,656 | $25K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,879 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 214 | $25K |
| 93971 | <1% | 307 | $24K | |
| 72050 | <1% | 338 | $23K | |
| 97010 | <1% | 5,754 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 139 | $21K |
| 70486 | <1% | 93 | $21K | |
| 86900 | <1% | 3,126 | $20K | |
| 82962 | <1% | 6,768 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,060 | $20K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,210 | $20K |
| 85730 | <1% | 7,954 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,764 | $19K |
| 77066 | Tomosynthesis, mammo | <1% | 85 | $19K |
| 87040 | <1% | 2,245 | $17K | |
| 97802 | <1% | 27 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,681 | $17K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 194 | $16K |
| 83605 | <1% | 2,164 | $16K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,238 | $16K |
| 94727 | <1% | 279 | $16K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,497 | $16K |
| 86901 | <1% | 2,488 | $15K | |
| 71250 | <1% | 116 | $15K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 683 | $15K |
| 85027 | <1% | 3,857 | $14K | |
| 94729 | <1% | 279 | $14K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,065 | $14K |
| 57500 | <1% | 25 | $14K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 120 | $14K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,344 | $13K |
| 97162 | <1% | 203 | $13K | |
| 87077 | <1% | 1,946 | $13K | |
| 97124 | <1% | 542 | $13K | |
| 19083 | <1% | 12 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,743 | $12K |
| 81003 | <1% | 5,541 | $11K | |
| 12001 | <1% | 115 | $11K | |
| 74018 | <1% | 230 | $11K | |
| 97014 | <1% | 612 | $11K | |
| OP278 | <1% | 14 | $10K | |
| 80061 | Lipid panel | <1% | 1,319 | $10K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 8,660 | $9K |
| 85379 | <1% | 2,009 | $9K | |
| 83735 | <1% | 3,050 | $9K | |
| 73080 | <1% | 113 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 207 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 267 | $8K |
| 82947 | <1% | 1,992 | $8K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 35 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 267 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,008 | $7K |
| 96376 | <1% | 239 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,644 | $7K |
| 82150 | <1% | 1,318 | $7K | |
| 0012A | <1% | 222 | $6K | |
| 29125 | <1% | 157 | $6K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,228 | $6K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 61 | $6K |
| 82550 | <1% | 1,672 | $6K | |
| 80076 | <1% | 1,405 | $6K | |
| 97164 | <1% | 146 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,327 | $5K |
| 87420 | <1% | 525 | $5K | |
| 72040 | <1% | 68 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,034 | $5K |
| 72081 | <1% | 87 | $5K | |
| 74178 | <1% | 16 | $5K | |
| 82948 | <1% | 1,650 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,227 | $5K |
| 85007 | <1% | 2,431 | $5K | |
| 87205 | <1% | 1,285 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,133 | $4K |
| 0002A | <1% | 119 | $4K | |
| 76000 | <1% | 42 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 436 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 609 | $3K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,469 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 212 | $2K |
| 0011A | <1% | 89 | $2K | |
| 74022 | <1% | 56 | $2K | |
| 72131 | <1% | 17 | $2K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 840 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 25 | $2K |
| 84100 | <1% | 1,146 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 957 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 67 | $2K |
| 88307 | <1% | 25 | $2K | |
| 71100 | <1% | 53 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 141 | $2K |
| 0001A | <1% | 63 | $2K | |
| 84703 | <1% | 254 | $1K | |
| 93925 | <1% | 14 | $1K | |
| 71101 | <1% | 32 | $1K | |
| 72072 | <1% | 25 | $1K | |
| 88312 | <1% | 38 | $1K | |
| 96367 | <1% | 27 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 745 | $1K |
| 80329 | <1% | 46 | $1K | |
| 73620 | <1% | 38 | $1K | |
| OP229 | <1% | 26 | $1K | |
| 76001 | <1% | 12 | $1K | |
| 74019 | <1% | 21 | $1K | |
| 87075 | <1% | 204 | $918.21 | |
| 73590 | <1% | 13 | $882.84 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 458 | $847.82 |
| 12002 | <1% | 13 | $833.42 | |
| J1815 | Injection, insulin, per 5 units | <1% | 469 | $754.96 |
| 97116 | <1% | 43 | $745.08 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 120 | $730.85 |
| 87590 | <1% | 56 | $730.66 | |
| 73560 | <1% | 14 | $721.59 | |
| 88341 | <1% | 31 | $720.66 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 48 | $691.25 |
| 82607 | <1% | 120 | $663.79 | |
| 84145 | <1% | 58 | $630.95 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 623 | $606.09 |
| 84436 | <1% | 132 | $603.82 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 13 | $592.89 |
| 73090 | <1% | 16 | $567.58 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 63 | $474.46 |
| 0003A | <1% | 12 | $405.05 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 16 | $370.52 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 429 | $345.99 |
| 77062 | <1% | 12 | $342.94 | |
| 82805 | <1% | 26 | $336.68 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 18 | $321.68 |
| 84439 | <1% | 58 | $312.02 | |
| 36416 | <1% | 139 | $282.02 | |
| 86701 | <1% | 45 | $277.50 | |
| 88302 | <1% | 25 | $254.25 | |
| 0064A | <1% | 14 | $250.66 | |
| 76937 | <1% | 64 | $244.37 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 453 | $242.39 |
| OP258 | <1% | 109 | $237.98 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 68 | $223.76 |
| 87807 | <1% | 40 | $208.56 | |
| 85652 | <1% | 101 | $203.07 | |
| 86695 | <1% | 24 | $200.60 | |
| 86140 | <1% | 51 | $188.76 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 55 | $166.91 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 74 | $161.20 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 207 | $149.46 |
| 82043 | <1% | 39 | $147.20 | |
| 86592 | <1% | 77 | $126.16 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 13 | $106.93 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 33 | $102.66 |
| 80331 | <1% | 12 | $96.94 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 24 | $96.27 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $82.60 |
| 86803 | <1% | 12 | $77.02 | |
| A4657 | Syringe, with or without needle, each | <1% | 65 | $76.99 |
| A4930 | Gloves, sterile, per pair | <1% | 17 | $73.39 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 86 | $72.65 |
| 82247 | <1% | 13 | $63.96 | |
| A4615 | Cannula, nasal | <1% | 67 | $63.38 |
| 82009 | <1% | 12 | $61.13 | |
| 82248 | <1% | 12 | $57.40 | |
| 82746 | <1% | 12 | $56.96 | |
| 87073 | <1% | 15 | $52.03 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $47.88 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 47 | $47.29 |
| 83550 | <1% | 14 | $43.78 | |
| 85347 | <1% | 16 | $34.23 | |
| 85651 | <1% | 41 | $30.88 | |
| 83540 | <1% | 14 | $29.36 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 104 | $24.04 |
| A4215 | Needle, sterile, any size, each | <1% | 47 | $21.39 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 50 | $19.18 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 13 | $15.32 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 14 | $8.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHELL, TROY (SECRETARY, GENERAL COUNSEL)
| Provider | Location | Paid |
|---|---|---|
| Prime Healthcare Anaheim, LLC | Anaheim, CA | $8.85M |
| Prime Healthcare Services - ST. Mary's Passaic, LLC | Passaic, NJ | $7.25M |
| Prime Healthcare Services Encino LLC | Encino, CA | $1.52M |
| Prime Healthcare Services - ST. Mary's Passaic, LLC | Passaic, NJ | $342K |
| Prime Healthcare Services - ST. Mary's Passaic, LLC | Passaic, NJ | $9K |
| Prime Healthcare Centinela LLC | Inglewood, CA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.